GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus (Q38040314)

27 August 2017

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus (English)

1 reference

27 August 2017

0 references

Juris J Meier

1

1 reference

27 August 2017

4 September 2012

1 reference

Nature Reviews Endocrinology

27 August 2017

1 reference

27 August 2017

8

1 reference

27 August 2017

728-742

1 reference

27 August 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2012.140

27 August 2017

0 references

cites work

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Incretin effect due to increased secretion and decreased clearance of insulin in normal humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

The incretin concept today

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

A Gastric Inhibitory Polypeptide II: The Complete Amino Acid Sequence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Further purification of a polypeptide demonstrating enterogastrone activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Exon duplication and divergence in the human preproglucagon gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Combined thiazolidinedione-metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Glucagon-like peptide containing pathways in the regulation of feeding behaviour

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

A role for glucagon-like peptide-1 in the central regulation of feeding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Individualised incretin-based treatment for type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Incretin-based therapies for type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Hyperamylasaemia and/or hyperlipasaemia: Incidence and underlying causes in hospitalized patients with non-pancreatic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

A thorough QT study to evaluate the effects of singledose exenatide 10 μg on cardiac repolarization in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Treatment of type 2 diabetes with incretin-based therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Effect of GLP-1 on lipid metabolism in human adipocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Glucagon-like peptide 1: a potent glycogenic hormone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.140

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas

31 March 2020

1 reference

12 December 2020

Crystal structure of human serum albumin at 2.5 A resolution

1 reference

12 December 2020

Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms.

1 reference

12 December 2020

Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat.

1 reference

12 December 2020

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

1 reference

12 December 2020

Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

1 reference

12 December 2020

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

1 reference

12 December 2020

Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2012.140

1 reference

27 August 2017

1 reference

PubMed ID

22945360